Relevant Publications
Metabolic
Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study
- Hazel et al
- 2021
Journal of Clinical Psychopharmacology: August 6, 2021
Metabolic
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
- Pivonello et al
- 2021
- 662865
Front. Endocrinol., 14 July 2021
Oncology
Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
- Greenstein et al.
- 2020
AACR Annual Meeting 2020
Oncology
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.
- Greenstein et al.
- 2020
Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)
Metabolic
Reversal of Antipsychotic-Induced Weight Gain in Rats with Miricorilant, a Selective Glucocorticoid Receptor (GR) Modulator
- Lee et al.
- 2020
2020 Annual Meeting - American Psychiatric Association (APA)
Metabolic
GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
- Auchus et al.
- 2020
J Endocr Soc. Vol 4, Issue Suppl 1 April-May
Metabolic
Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism
- Pivonello et al.
- 2019
American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress
Metabolic
Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice
- Koorneef et al.
- 2018
- 30321321
Endocrinology. 2018, 159(12):3925–3936
Other
Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.
- Hunt et al.
- 2017
- 28967708
Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.